Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials

Overview of attention for article published in The Lancet Respiratory Medicine, August 2014

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (96th percentile)
High Attention Score compared to outputs of the same age and source (88th percentile)

So far, Altmetric has seen 4 news stories from 3 outlets.

2つの同一のランダム化試験において、新しい噴霧製剤の古い抗生物質は気管支拡張症の患者に対する利点に関してさまざまな結果を示しました。緑膿菌感染症の可能性もあるが、研究者らは、1回の試験で否定的な結果が出た原因を特定したと述べている。 PROMIS-I試験…

Meeting Coverage > ERS One negative trial in the phase III PROMIS program blamed squarely on the COVID-19 pandemic by Ian Ingram…

Gilead Sciences, a leader in therapeutic development for lung diseases, investigated the use of the Respiratory Domain of the…

A study from a Phase 3 trial on an inhaled antibiotic therapy for non-cystic fibrosis bronchiectasis entitled “Aztreonam for…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity.